Expression Profiling and Proteomic Analysis of JIN Chinese Herbal Formula in Lung Carcinoma H460 Xenografts

• Type of Material: Article
• Authors: Luyu Zheng, Nanjing University; Weiyi Zhang, Zhejiang University; Miao Jiang, Nanjing University; Huarong Zhang, Zhejiang University; Fei Xiong, Nanjing University; Yang Yu, Nanjing University; Meijuan Chen, Nanjing University; Jing Zhou, Nanjing University; Xiaoming Dai, Nanjing University; Yuping Tang, Nanjing University; Ming Jiang, Hong Kong Baptist University; Mingyan Wang, Nanjing University; Ge Cheng, Nanjing University; Jinao Duan, Nanjing University; Wei Yu, Zhejiang University; Biaoyang Lin, Zhejiang University; Haian Fu, Emory University; Xu Zhang, Nanjing University
• Language: English
• Date: 2013-01-01
• Publisher: Hindawi Publishing Corporation
• Publication Version: Final Published Version
• Copyright Statement: © 2013 Luyu Zheng et al.
• License: Creative Commons Attribution 3.0 Unported
• Final Published Version (URL): http://dx.doi.org/10.1155/2013/160168
• Title of Journal or Parent Work: Evidence-Based Complementary and Alternative Medicine
• ISSN: 1741-427X
• Volume: 2013
• Start Page: 1
• End Page: 10
• Grant/Funding Information: This study is supported in part by the National Science and Technology Pillar Program in the 11th Five-year Plan of China (Grant no. 2006BAI11B08-01, for H. Fu and X. Zhang), Priority Academic Program Development of Jiangsu Higher Education Institution (for X. Zhang), and the Ministry of Science and Technology of China (Grant no. 2006DFA32950, for B. Lin).
• Keywords: GOMINER; Science & Technology; Life Sciences & Biomedicine; CANCER; Integrative & Complementary Medicine; PIPELINE; THERAPY; CHAPERONES; PROTEINS; CELLS
• Research Categories: Health Sciences, Public Health; Health Sciences, Oncology

Abstract

Many traditional Chinese medicine (TCM) formulae have been used in cancer therapy. The JIN formula is an ancient herbal formula recorded in the classic TCM book Jin Kui Yao Lue (Golden Chamber). The JIN formula significantly delayed the growth of subcutaneous human H460 xenografted tumors in vivo compared with the growth of mock controls. Gene array analysis of signal transduction in cancer showed that the JIN formula acted on multiple targets such as the mitogen-activated protein kinase, hedgehog, and Wnt signaling pathways. The coformula treatment of JIN and diamminedichloroplatinum (DDP) affected the stress/heat shock pathway. Proteomic analysis showed 36 and 84 differentially expressed proteins between the mock and DDP groups and between the mock and JIN groups, respectively. GoMiner analysis revealed that the differentially expressed proteins between the JIN and mock groups were enriched during cellular metabolic processes, and so forth. The ones between the DDP and mock groups were enriched during protein-DNA complex assembly, and so forth. Most downregulated proteins in the JIN group were heat shock proteins (HSPs) such as HSP90AA1 and HSPA1B, which could be used as markers to monitor responses to the JIN formula therapy. The mechanism of action of the JIN formula on HSP proteins warrants further investigation.